Veracyte, Inc. · NASDAQ:VCYT
Veracyte — Merger or Acquisition (February 2021)
18 slides from Veracyte's merger presentation, Feb 3, 2021
Slide 1: Decipher Biosciences Acquisition Further Solidifies Global Leadership in Cancer Diagnostics and Accelerates Growth
Decipher Biosciences Acquisition Further Solidifies Global Leadership in Cancer Diagnostics and Accelerates Growth ANSWERS February 3, 2021 ® Veracyte, Inc. All rights reserved.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the pending acquisition of Decipher Biosciences; statements regarding
Slide 3: Our vision is to improve outcomes for patients all over the world
Our vision is to improve outcomes for patients all over the world at every step of their journey. ® Veracyte, Inc. All rights reserved. February 3, 2021 February 3, 2021 ® Veracyte, Inc. All rights reserved.
Slide 4: Genomic tests targeting multiple diseases across care continuum
Genomic tests targeting multiple diseases across care continuum Veracyte today February 3, 2021 ® Veracyte, Inc. All rights reserved. 1Investigational product 2Percepta Genomic Atlas is US only Basel Nasal Swab Test Lum A/B Pre-Cancer Detection Treatment LymphMark™ Nasal Swab Test Early Detection Di
Slide 5: A global platform for international expansion
nCounter Nasal Swab LymphMark™ CLIA LAB Nasal Swab LymphMark™ LymphMark™ A global platform for international expansion Veracyte today ® Veracyte, Inc. All rights reserved. February 3, 2021 February 3, 2021 ® Veracyte, Inc. All rights reserved.
Slide 6: Combination creates comprehensive portfolio addressing 7 of top 10 cancers
February 3, 2021 ® Veracyte, Inc. All rights reserved. Drives market, menu and global expansion Accelerates growth Combination creates comprehensive portfolio of novel genomic diagnostic tests addressing 7 of the top 10 cancers
Slide 7: A market leader in urologic cancer genomic diagnostics
A market leader in urologic cancer genomic diagnostics Decipher Biosciences overview Commercial-stage precision oncology company focused on $2B urologic cancer market Approximately 100 full-time employees, large CLIA- and CAP-certified lab in San Diego Unique product portfolio spanning the entire lo
Slide 8: Significant commercial traction in large markets
Significant commercial traction in large markets Decipher Biosciences urologic cancer tests Product Portfolio Product Indications 2020 U.S. Estimated Incidence1 Clinical Evidence Commercialization Analytic Validation Clinical Validation Clinical Utility Medicare Coverage NCCN Guideline Inclusion Com
Slide 9: Enables physicians to personalize treatment across localized disease
Enables physicians to personalize treatment across localized disease Decipher Biosciences in prostate cancer February 3 , 2021 ® Veracyte, Inc. All rights reserved. Initial Management Definitive Therapy After Surgery At BCR Active Surveillance or Treat? Treatment Intensity? Early or Salvage Radiatio
Slide 10: Comprehensive urologic cancer biorepository to drive further value
Comprehensive urologic cancer biorepository to drive further value Decipher GRID >300 Clinically Validated Prognostic/Predictive Signatures supported by >200 publications Genomics & Proprietary Signatures >15,000 Patients from Clinical Trials Clinical Trials Community Patients from >3,200 U.S. Physi
Slide 11: Market and menu expansion accelerates growth
Market and menu expansion accelerates growth ~680,000 patients/year ~1,100,000 patients/year VERACYTE Addressing 4 of top 10 cancers VERACYTE + Decipher Biosciences Addressing 7 of top 10 cancers ~60% increase Top cancers in US by incidence $2B+ TAM in US alone ® Veracyte, Inc. All rights reserved.
Slide 12: Further solidifies our global leadership
LymphMark™ CLIA LAB Nasal Swab LymphMark™ Further solidifies our global leadership February 3, 2021 ® Veracyte, Inc. All rights reserved. ~$50+ BILLION LONG-TERM GLOBAL TAM CLIA LAB Decipher: Prostate Decipher: Bladder Decipher: Kidney nCounter Transplant Decipher: Prostate Decipher: Bladder Deciphe
Slide 13: Accelerates our strategic growth pathway
Accelerates our strategic growth pathway February 3, 2021 Whole transcriptome sequencing and machine learning Strategic partnerships Menu expansion Global diagnostic testing and platform leader Atlas Xpression Atlas Nasal Swab IPF Prognostic LymphMark™ Scientific Excellence Channel Expansion Menu Ex
Slide 14: Accelerating Revenue Growth and Pathway to Profitability
+37% 139% YoY +106% Accelerating Revenue Growth and Pathway to Profitability Illustrative Pro Forma Financials ($ in millions) Decipher Biosciences Historical Standalone Revenue2020 Pro Forma[2021 Guidance] Veracyte Q4 2020 Annualized +30% Revenue Growth Revenue Growth +31% (2)% YoY +16% Source: * F
Slide 15: Excited to welcome Decipher Biosciences leadership and team to Veracyte
Excited to welcome Decipher Biosciences leadership and team to Veracyte February 3, 2021 ® Veracyte, Inc. All rights reserved. Ryan Dittamore, Chief Business Officer & Head of Product Development Tina Nova, PhD, President & CEO Elai Davicioni, PhD, founder and chief scientific officer Bashar Dabbas,
Slide 16: The plan once the merger closes
The plan once the merger closes Tina will assume role of General Manager, Urologic Cancer Business, reporting to me Brent Vetter will report to our CFO and COO, Keith Kennedy All other functions will continue to report through current leaders in the organization to Tina Employee healthcare benefits
Slide 17: Key ground rules until merger closes
Key ground rules until merger closes Antitrust laws require Veracyte and Delight to continue to operate independently pre-close Must limit any collaborative activities and information exchanges solely to that necessary to plan for post-close integration Parties cannot: Implement changes to product d
Slide 18: Wvera cyte.
Wvera cyte.